



(51) International Patent Classification:

C07K 14/71 (2006.01) *A61P 19/00* (2006.01)
A61K 38/18 (2006.01) *C12N 15/12* (2006.01)
A61K 47/68 (2017.01) *C12N 15/63* (2006.01)
A61P 11/00 (2006.01) *C07K 14/495* (2006.01)

(21) International Application Number:

PCT/CA2021/050795

(22) International Filing Date:

11 June 2021 (11.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/038,290 12 June 2020 (12.06.2020) US

(71) Applicant: **BRISTOL-MYERS SQUIBB TGF BETA INC.** [CA/CA]; 750 Boul. Saint-Laurent, Suite 101, Montreal, Québec H2Y 2Z4 (CA).


(72) Inventors: **O'CONNOR, Maureen**; 186 Sherbrooke Street, Beaconsfield, Québec H9W 1P2 (CA). **TREMBLAY, Gilles**; 100 Rue Denise-Lemaistre, La Prairie, Québec J5R 6N8 (CA). **DENIS, Jean-francois**; 45 Rue Trillium, Dollard-des-Ormeaux, Québec H9B 1T3 (CA). **GANESH, Vannakambadi K.**; 2515 Lansing Circle, Pearland, Texas 77584 (US).

(74) Agent: **SMART & BIGGAR LLP**; P.O. Box 2999, Station D., 900-55 Metcalfe Street, Ottawa, Ontario K1P 5Y6 (CA).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: TRANSFORMING GROWTH FACTOR BETA (TGFβ) BINDING AGENTS AND USES THEREOF

FIG. 1



(57) Abstract: There are provided tetraivalent TGFβ receptor-ectodomain based traps having a tailored isoform-specificity profile for neutralization of TGFβ ligands, and methods of use thereof in the treatment of diseases and conditions associated with TGFβ, particularly TGFβ1 and TGFβ3. In particular, there are provided TGFβ binding agents designed to tailor TGFβ isoform specificity, in order to maximize therapeutic efficacy in specific disease indications while minimizing adverse effects. The TGFβ binding agents comprise two polypeptides assembled via a multimerization domain, each polypeptide having two TGFβII receptor (TGFβR) ligand-binding domains linked as a doublet, wherein the linkers are selected to tailor isoform specificity.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE